1. Abram AK (2017) Determination that REVEX (nalmefene hydrochloride injection), 0.1 milligram base/milliliter and 1.0 milligram base/milliliter, was not withdrawn from sale for reasons of safety or effectiveness. U.S. Food and Drug Administration. https://www.federalregister.gov/d/2017-23952
2. Adapt Pharma Operations Limited (2016) FDA advisory committee on the most appropriate dose or doses of naloxone to reverse the effects of fife-threatening opioid overdose in the community settings. https://www.fda.gov/media/100409/download
3. Adapt Pharma Operations Limited (2019) Narcan nasal spray package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208411s001lbl.pdf
4. Ahmad FB, Rossen LM, Sutton P (2021) Provisional drug overdose death counts. Center for Disease Control and Prevention, National Center for Health Statistics. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
5. Ahonen J, Olkkola KT, Hynynen M, Seppälä T, Ikävalko H, Remmerie B, Salmenperä M (2000) Comparison of alfentanil fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. Br J Anaesth 85:533–540. https://doi.org/10.1093/bja/85.4.533